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Glial cells, consisting of microglia, astrocytes, and oligodendrocyte lineage cells as
their major components, constitute a large fraction of the mammalian brain. Originally
considered as purely non-functional glue for neurons, decades of research have
highlighted the importance as well as further functions of glial cells. Although many
aspects of these cells are well characterized nowadays, the functions of the different glial
populations in the brain under both physiological and pathological conditions remain,
at least to a certain extent, unresolved. To tackle these important questions, a broad
range of depletion approaches have been developed in which microglia, astrocytes,
or oligodendrocyte lineage cells (i.e., NG2-glia and oligodendrocytes) are specifically
ablated from the adult brain network with a subsequent analysis of the consequences.
As the different glial populations are very heterogeneous, it is imperative to specifically
ablate single cell populations instead of inducing cell death in all glial cells in general.
Thanks to modern genetic manipulation methods, the approaches can now directly
be targeted to the cell type of interest making the ablation more specific compared to
general cell ablation approaches that have been used earlier on. In this review, we will
give a detailed summary on different glial ablation studies, focusing on the adult mouse
central nervous system and the functional readouts. We will also provide an outlook on
how these approaches could be further exploited in the future.
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INTRODUCTION
Glial cells were first identified by the 19th century’s leading neuroscientists including Rudolf
Virchow, Santiago Ramón y Cajal and Pío del Río-Hortega. At that time, glia were suggested to
solely function as so-called “Nervenkitt” (the German word for nerve glue). This is also reflected in
the name “glial cell” derived from the ancient Greek word “glía” meaning “glue” in English. With
time, scientists started to speculate about additional possible roles of these cells. Although many
studies have been performed to specify these further roles, the full properties of glial cells remain
unresolved. Moreover, glial cells are anything but a minor cellular fraction, as they constitute –
depending on the mammalian species – between 33 and 66% of the total brain mass (Azevedo et al.,
2009; Herculano-Houzel, 2014). Recent findings have made it clear that glial cells are more than
just mere “Nervenkitt”. The total glial cell population can be subdivided into four major groups:
(1) microglia, (2) astrocytes, (3) oligodendrocytes, and (4) their progenitors NG2-glia. This review
will focus on the research of the past decades addressing the role of these four major glial cell types
in regard to the function of the adult brain.
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The analysis of cellular function can be addressed through
a range of different experimental measures. One common
technique involves the depletion of mature brain cells that are
already integrated in an established network in vivo. During the
last two decades, various ways have been developed to achieve this
goal. Initially, cytotoxic substances, such as ethidium bromide
(EtBr) that are lethal for cells in general (including neurons)
were used (Yajima and Suzuki, 1979). To specifically target and
subsequently ablate cycling cells, the application of high doses of
X-irradiation (Kalderon and Fuks, 1996; Chari and Blakemore,
2002) or of the mitotic blocker arabinofuranosyl cytidine (AraC,
Doetsch et al., 1999) to the tissue of interest has also proven to be
successful. These general ablation approaches, which are still in
use today, were likely favored due to the simplicity of application
and due to the lack of more specific alternatives. X-irradiation
as well as the application of AraC is not cell type specific, as all
cycling cells in the area (X-irradiation) or tissue (AraC) of interest
undergo induced cell death. Therefore these approaches are not
ideal to identify the function of a specific cell type. The same is
true for EtBr, as it induces general unrepairable DNA damage
leading to cell death (Yajima and Suzuki, 1979; Johnson et al.,
2003). The use of such general approaches has decreased, as drugs
can have effects in other tissues that lead to secondary damage
or even changes in the cells of interest. As genetic manipulation
has become easier and more accessible within the recent years,
cell ablation techniques have also improved. Nowadays, most
ablation approaches make use of a cell type or a region-specific
promoter that is coupled with a “suicide” gene, resulting in
depletion of distinct cell types. Suicide genes typically encode
either a toxin, an enzyme that converts a pro-drug into a toxic
agent, or an essential protein for the specific cell type leading to
apoptotic cell death specifically in the cells of interest. The main
advantage of these approaches is that they have few side effects
for surrounding cells or other tissues.
Application of these ablation methods have already helped us
to better understand the functions of all four major glial cell types
in the adult brain. This review will summarize and discuss the
major findings of ablation studies performed during the last few
decades.
MICROGLIA
Microglia Ablation under Healthy
Conditions
In a very simplified view, microglia are the immunocompetent
and phagocytic cells of the nervous system. Although they are
part of the brain’s glia, they do not originate from the ectodermal
tissue like all other glial cells, but from yolk-sac progenitors that
only populate the brain during development (reviewed in Kim
and de Vellis, 2005; Kettenmann et al., 2011). Microglia have been
shown to cover a huge volume of the adult brain parenchyma,
with individual non-overlapping domains constantly sensing the
environment through rapid movements of their fine filopodia,
which react to any kind of insult (Nimmerjahn et al., 2005; Cronk
and Kipnis, 2013). As microglia in the brain have the same origin
and express many common cellular markers with peripheral
macrophages/monocytes, it has proven difficult to only ablate
one but not the other cell type (Silver et al., 2015). Additionally,
macrophages are able to invade the brain upon injury or any
other disturbance of the blood brain barrier (BBB), meaning that
the roles of microglia and macrophages have been difficult to
disentangle (Pineau et al., 2010). Several of the microglia ablation
studies tried to address the issue of how these cells maintain their
homeostasis in the adult healthy brain. Microglia could either
derive from a brain intrinsic stem cell source or from a peripheral
derived progenitor originating from the same developmental
source that infiltrates the brain at some stage and contributes to
the microglia population. From these studies, it seemed that at
least under physiological conditions the two populations remain
separated (see below). In addition, there is the question about
other roles played by microglia besides surveying the healthy
tissue, as microglia have been shown to be major players in
synaptic pruning during development (reviewed in Wu et al.,
2015) and in synaptic modulation both in normal as well as
under pathological conditions (Bessis et al., 2007; Hong et al.,
2016a,b; Vasek et al., 2016). Further microglia ablation studies
could therefore provide a potential tool to describe yet unknown
microglia-associated functions in adult brain physiology.
Although several studies have depleted myeloid cells –
including microglia – during development by inserting
deleterious mutations in macrophage-specific genes (reviewed in
Waisman et al., 2015), this review will focus only on microglia
ablation studies performed in the adult brain.
To successfully ablate adult microglia, pharmacological and
genetic strategies have been developed (for summary and details
see Table 1). As a pharmacological approach, the use of the
systemically administered drug PLX3397, which specifically
targets Colony-stimulating factor 1 receptor (CSF-1R) signaling,
has been well established. CSF-1R is uniquely expressed on
myeloid cells including brain resident microglia, making only
these cells susceptible to death (Elmore et al., 2014). The use
of clodronate liposomes (CLs) is a second pharmacological way
to specifically deplete phagocytic cells, including microglia (van
Rooijen et al., 1990). After the phagocytic cells take up the
liposomal particles and release the encapsulated, toxic clodronate
they undergo apoptosis. As a genetic approach, the diphtheria
toxin (DT) or its subunit A (DTA), originally derived from the
bacterium Corynebacterium diphtheriae, is a widely used suicide
gene that has already been applied in ablation approaches. Its
mode of action is the cytosolic inhibition of cellular protein
synthesis, leading to cell death (Honjo et al., 1968). The DT-
dependent ablation system can be used in two ways: (1) direct
tamoxifen-inducible expression of the DT(A) in the target cells or
(2) cell type-specific expression of the diphtheria toxin receptor
(DTR) in combination with the systemic application of DT(A),
such that only cells carrying the receptor are susceptible to death.
Independent of methodology (pharmacological or genetic), all of
these approaches achieve fast and robust microglia death in the
brain, ranging from 80 to >99% depending on the treatment and
the region of interest (Parkhurst et al., 2013; Elmore et al., 2014,
2015; Bruttger et al., 2015; Torres et al., 2016).
Another commonly identified microglia property is their
repopulation capacity: around 1 week after depletion,
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TABLE 1 | Microglial ablation approaches under healthy and pathological conditions.
Cell type Condition Method Efficiency (%) Physiological effect Reference
Microglia Health PLX3397 >99 Fast repopulation, no negative outcome Elmore et al., 2014, 2015
PLX3397, clodronate
liposomes (CLs)
∼80 Transient and reversible changes in spatial
memory and social behavior
Torres et al., 2016
CX3CR1CreER:iDTR mouse
line
>90 Loss of synapse formation, negative effect on
learning tasks
Parkhurst et al., 2013
CX3CR1CreER:iDTR mouse
line
>90 Fast repopulation, no negative outcome Bruttger et al., 2015
Pathology PLX3397, CLs 70–90 Amelioration of tauopathy and neurotoxicity in AD
mouse models
Asai et al., 2015
PLX3397 93–97 Bigger infarct size and dysregulation of neuronal
signaling leading to neuronal death in middle
cerebral artery occlusion (MCAO)
Szalay et al., 2016
CD11b-HSVTK mouse line >90 Repression of inflammation in EAE Heppner et al., 2005
CD11b-HSVTK mouse line 90 No effects on ameloyd plaque formation or
neuritic dystrophy in AD
Grathwohl et al., 2009
CD11b-HSVTKmt−30
mouse line
50 No effect on disease outcome or neuronal
survival in EAE
Gowing et al., 2008
CD11b-HSVTKmt−30
mouse line
75 No effect on neuronal survival after mechanical
injury
Gowing et al., 2006
CD11b-HSVTK mouse line 80–90 No effect on seizure sensitivity in temporal lobe
epilepsy (TLE)
Mirrione et al., 2010
CD11b-HSVTK mouse line 75 Bigger infarct size and neuronal death in MCAO Lalancette-Hebert et al., 2007
the whole population is restored without obvious deficits
in microglia or in other glial cell populations. With this
experimental system, one group identified a local progenitor
cell population in the brain parenchyma expressing the stem
cell marker nestin that accounted for the rapid repopulation
of microglia. The cellular characteristics of these progenitors
were, however, not described further (Elmore et al., 2014,
2015).
Although demonstrating a similar microglia repopulation
capacity, Bruttger et al. (2015) could not identify a separate
repopulating progenitor pool but rather demonstrated a fast
spreading distribution of local proliferating microglia that were
able to escape the ablation treatment (∼5–10%). Some of these
locally repopulating central nervous system (CNS) microglia
also co-expressed nestin together with the microglial marker
Iba1. This lead to the speculation that the nestin positive
cells described in Elmore et al. (2014, 2015) are not a novel
local progenitor pool but rather reactive microglia, as already
shown for reactive astrocytes (Clarke et al., 1994). The observed
identity differences in the repopulating pool could be due to
distinct ablation approaches, as one analysis used PLX3397
to deplete microglia (Elmore et al., 2014, 2015), whilst the
others used a mouse line in which iDTR-expression was driven
by the fractalkine receptor CX3CR1 (CX3CR1CreER:iDTR) that
is specifically expressed on microglia (Parkhurst et al., 2013;
Bruttger et al., 2015). Myeloid cells in the periphery are equally
targeted and depleted during PLX3397 treatment, which could,
to some extent, affect the outcome of the analysis or even result
in changes of the repopulating microglia cells. Another pitfall of
the pharmacological approach could be CSF-1R expression on
other cells within the brain that are not microglia which might
therefore be targeted and ablated and hence lead to secondary
effects in the brain. CX3CR1 is also highly expressed in peripheral
macrophages (Geissmann et al., 2010). In the case of the inducible
DTR-system, the peripheral cells were affected to a lesser extent.
These cells have a high turnover from their stem cell source
in comparison to resting microglia in the CNS and therefore
lose the CreER-expression after tamoxifen treatment with time.
Hence, DTA-application only affects persisting microglia but
not the short-lived peripheral myeloid cells (Bruttger et al.,
2015). The difference in the targeting specificity of these
methods could account for the differences observed in these
studies.
Although the aforementioned studies demonstrated
comparable ablation and repopulation dynamics, the ideas
about microglia function in the healthy adult brain are very
different. Three studies performed in naïve, healthy young adult
animals did not find any gross cellular changes or pathologies
in microglia-ablated mice besides mild astrogliosis and a
short cytokine storm where pro-inflammatory cytokines were
highly up-regulated for a short time (Elmore et al., 2014, 2015;
Bruttger et al., 2015). Parkhurst et al. (2013) on the other
hand, reported a loss of motor-dependent synapse formation
and decreased performance in learning tasks that seemed to
be dependent on brain-derived neurotrophic factor (BDNF)
signaling (Figure 1). Similarly, a loss of ∼80% of hippocampal
microglia resulted in alterations in the social behavior of adult
mice (Torres et al., 2016). These alterations were most likely
induced by the direct microglia modulation of the number of
functional neuronal synapses, as previously demonstrated by
the same group using an ex vivo approach where microglia
were depleted in slice cultures by addition of CLs, resulting in
a direct increase in the synaptic activity of neurons (Ji et al.,
2013). The major methodological differences between these
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FIGURE 1 | Effects and dynamics of microglia ablation under healthy
and pathological conditions. Under physiological conditions (left green
panel) successful microglia ablation has been achieved by the use of the
pharmacological inhibitors PLX3397 and clodronate liposomes (CLs) or the
CX3CR1-iDTR mouse lines. After approximately 1 week, the microglia
population was completely restored from a nestin+ progenitor pool.
Depending on the study, the ablation had either no physiological effect or it
influenced the motor-dependent synapse formation and led to a poor
performance in learning tasks. Under various pathological conditions (right
orange panel) the ablation was also induced with PLX3397, CL or different
CD11b-HSVTK mouse lines, however, with very controversial outcomes.
While the microglia ablation had positive effects on the pathology of
experimental autoimmune encephalomyelitis (EAE) or the tauopathy of
Alzheimer’s disease (AD), it did not influence the pathology of amyloid plaque
deposition in AD, mechanical injury, amyotrophic lateral sclerosis (ALS), or
temporal lobe epilepsy (TLE) and even negatively affected the outcome of a
middle cerebral artery occlusion (MCAO).
approaches may explain the discrepancies in the results of these
studies. These differences include the cloning strategy of the
CX3CR1CreER- and the iDTR-locus and the induction protocol
used for the tamoxifen-inducible ablations, which could both
potentially result in a variable recombination rate with diverse
readouts. An additional difference is the maintenance of CNS
homeostasis after microglia ablation. While one study did not
report disturbances in brain homeostasis (Parkhurst et al.,
2013), the other observed mild astrogliosis and an increase
in pro-inflammatory signals, which could also differently
influence the synapse formation and behavior between the
approaches.
In summary, the ablation studies of microglia in the adult
healthy brain have revealed that these cells can, at least
transiently, easily and efficiently be eliminated from the adult
brain (summarized in Table 1), though surviving progenitors
rapidly repopulate the depleted areas. Moreover, microglia
homeostasis seems to play an important role in the ongoing
synapse formation in the brain; these specific functions as well
as mechanisms are however far from understood.
Microglia Ablation under Pathological
Conditions
Microglia are known to shift their phenotype from “resting”
to an “activated” state upon any loss of brain homeostasis
due to injury, infection, or neurodegenerative disease. This
microglia activation is comprised of proliferation, migration
toward a chemoattractant, reduction of cellular complexity as
well as phagocytosis to clear the damaged tissue (Kreutzberg,
1996; Hanisch and Kettenmann, 2007; Kettenmann et al.,
2011). The cellular response of microglia upon injury has been
extensively described, however, both its functional impact on
brain pathogenesis and its mechanism remain somewhat unclear.
Because many contradictory findings have been reported with
regard to microglia function after brain injury, microglia ablation
studies continue to be performed (for summary and comparison,
see Table 1 bottom part).
In the same vein as microglia ablation studies under healthy
conditions, the approaches used in disease models are mainly
the well-established pharmacological (PLX3397 and CLs) as well
as genetically-driven toxin methods, although predominantly
the latter (see Table 1 bottom part). Instead of the DTA- or
DTR-system, pathological conditions have been investigated with
a wildtype (TK) and a mutant (TKmt−30) thymidine kinase
of the herpes simplex virus (HSV; HSVTK). The HSVTK is
another commonly used suicide gene that only becomes toxic
after the application of antiviral prodrugs like ganciclovir (GCV).
These prodrugs are further processed into toxic triphosphates
by cell-intrinsic kinases, resulting in the apoptotic death of
cells. As TK mainly interferes with nucleosides and therefore
disrupts DNA-replication, it specifically ablates proliferating cells
rather than quiescent ones. As well as the wildtype thymidine
TK, the mutant improved form of this enzyme (TKmt−30)
exists. As an advantage, it shows an increased sensitivity to
the applied drugs, allowing lower doses of the systemic drug
and alleviating the male sterility that is a common problem
observed in TK-transgenic mice (Fyfe et al., 1978; Black et al.,
1996; Fischer et al., 2005). Unlike in the healthy CNS where
microglia-targeting was achieved with the CX3CR1-promoter
(see section Microglia Ablation under Healthy Conditions), all
studies investigating the role of microglia in disease models
use the CD11b-promoter that is also expressed in cells of
myeloid origin, including both microglia and macrophages
(Akiyama and McGeer, 1990; Dziennis et al., 1995). Most
interestingly, in this system GCV treatment and the subsequent
depletion of myeloid cells resulted in increased mortality
(Grathwohl et al., 2009) that could only be circumvented
by bone marrow transplantation. This method led to the
advantageous situation that only microglia were depleted while
keeping an intact blood circulation with wildtype myeloid
cells.
Although microglia ablation was successful in the different
studies, the quest for the role of microglia in disease models
opened at least as many questions as it resolved. Asai et al.
(2015) investigated the role of microglia in the tauopathy in
Alzheimer’s disease (AD) using both a virus-mediated model for
tau propagation and a transgenic model to ectopically express
the human form of the tau protein. They addressed the role
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of microglia in AD by depleting these cells in adult mice
(3.5 or 4.5 months). The depletion of 70–90% of microglia
(depending on the region and the treatment) ameliorated the
tauopathy as well as the neurotoxicity in these two mouse
models of AD, indicating the importance of microglia in the
progression of neurodegenerative diseases. Szalay et al. (2016)
achieved an almost complete (93–97%) ablation of microglia.
They addressed the functional outcome of microglial absence
after Middle Cerebral Artery Occlusion (MCAO) in adult mice
and found a striking increase in the infarcted area plus a
dysregulated neuronal calcium response that led to neuronal
death. This response was reversed with microglia repopulation,
and therefore this study further emphasizes the importance of
microglia in the pathological brain. While a >90% microglia
ablation seemed to have a positive effect on clinical scores
and inflammation in a model of experimental autoimmune
encephalomyelitis (EAE, Heppner et al., 2005), it was neither
beneficial nor deleterious in other disease models (see Figure 1).
Although the tauopathy of AD could be resolved (as explained
above), the 90% reduction of microglia did not affect amyloid
plaque formation or neuritic dystrophy in the same disease model
(Grathwohl et al., 2009), indicating that microglia only influence
some pathological properties of the disease. Similarly, in a genetic
model of amyotrophic lateral sclerosis (ALS, SOD1 mutation),
a 50% reduction of the microglia population altered neither
the disease outcome nor the degeneration of motor neurons
(Gowing et al., 2008). Furthermore, toxin-induced cell death of
about 75% of microglia after traumatic glossal nerve or cortical
stab wound injury also did not affect neuronal survival (Gowing
et al., 2006), indicating that a lack of any microglia ablation
benefit to neuronal survival is not specified to a particular
disease but in general to pathology. Although microglia are
known to actively influence and modulate neuronal synapses
under physiological conditions (Bessis et al., 2007), the absence
of a substantial number of microglia (80–90% depending on
the region) did not affect seizure sensitivity in a pilocarpine-
induced model of temporal lobe epilepsy (TLE, Mirrione et al.,
2010). Indeed, at least one study has shown the opposite: In
addition to not changing the disease outcome, Lalancette-Hebert
et al. (2007) reported a bigger infarct size and more damage to
brain tissue after MCAO following an ablation of microglia of
around 75%.
To explain these variable observations between ablation
studies, the same aspects that complicate the readout of the
approaches carried out under healthy conditions (see section
Microglia Ablation under Healthy Conditions) certainly apply
also here, and different disease models add another dimension
of complexity. Although all these studies worked with CD11b-
HSVTK transgenic mice, the ablation efficiency was highly
variable, ranging from 50 to up to 90%, making a direct
comparison between the models difficult. Besides the cloned
mouse lines carrying different transgenes, the diverse injury
paradigms that were performed in various CNS regions might
play an additional role. The injury paradigms were performed
at different ages of the experimental mice (ranging from 2 up to
4.5 months of age) and it could be possible that microglia function
changes during the process of aging.
Although microglia are well known to react with similar
morphological changes to different injuries and pathologies
(Kreutzberg, 1996; Hanisch and Kettenmann, 2007; Kettenmann
et al., 2011), it remains uncertain if the functional activation of
microglia in response to different insults varies depending on the
signals that are released from a specific type of pathology. The
temporal aspect of the disease model might additionally influence
the observations, depending on whether it is chronic (like in
the case of AD and ALS) or acute (e.g., MCAO and mechanical
brain injury). The idea that subtypes of activated microglia affect
disease outcome in different directions has long been proposed.
Classically-activated M1-like microglia were long thought to
have mainly pro-inflammatory functions and were therefore
considered to be “bad” for the outcome of the pathology,
while the alternatively-activated “good” M2-like microglia were
considered to be important for the anti-inflammatory functions
that minimize pathology (Kigerl et al., 2009; Varnum and Ikezu,
2012; Miron et al., 2013; Zhou et al., 2014). New research has
called this concept of clearly-polarized classes of microglia into
question, as the activation state of microglia might be dependent
on the stimulus (Kim et al., 2016; Ransohoff, 2016). Transferring
these findings to the above described ablation studies, it is still
not known whether the TK-induced ablation is preferentially
targeting a polarized subset of cells or the whole microglial
population, which would differentially influence the outcome
of the disease. Furthermore, it is unclear whether differentially-
activated macrophages become two different populations that
co-exist during the whole course of pathology or if they can inter-
convert at different stages (Varnum and Ikezu, 2012; Weisser
et al., 2013). If the latter hypothesis holds true, the timing of
the onset of the microglia ablation studies would play another
important factor that would need further consideration.
Taken together, it can be concluded that using different
approaches, activated microglia can also efficiently be depleted in
various kinds of brain pathologies, but the specific roles of these
cells in disease must be clarified with further studies.
ASTROCYTES
Astrocyte Ablation under Healthy
Conditions
Astrocytes represent the most abundant fraction of glial cell types
in the adult brain (Kettenmann and Ransom, 2005). Amongst
all glial cell types, several of the functional roles of astrocytes
in the healthy adult brain are already well described. These
functions are broad, spanning many aspects of brain physiology
and are so numerous that addressing all of them is far beyond
the scope of this review. In short, the maintenance of water and
ion homeostasis, the participation in the tripartite synapse as well
as the contribution to the BBB maintenance are among the most
important astrocytic functions (Kimelberg, 2010; Kimelberg and
Nedergaard, 2010).
Astrocytes are, assumedly due to their high abundance,
the best studied and most well described glial cell population
in the adult CNS. Therefore the idea to specifically ablate
astrocytes in order to find out their specific functions has been
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 February 2017 | Volume 11 | Article 24
fncel-11-00024 February 10, 2017 Time: 15:23 # 6
Jäkel and Dimou Glial Cell Ablation in the Adult
developed much earlier compared to other glial cell populations.
Nevertheless, there is only a small amount of ablation studies in
the field that target the astrocyte population under physiological
conditions.
To specifically deplete the astrocyte population in the adult
healthy brain, again both pharmacological as well as genetic
approaches are available and have been used (see Table 2). The
glutamate homologue L-α-aminoadipate (L-AAA) is the only
pharmacological approach to ablate astrocytes so far and was
shown to be a specific toxin for astrocytes rather than for neurons
or other glial cell types when locally injected into the site of
interest (Takada and Hattori, 1986; Nishimura et al., 2000).
Suicide gene expression exploited for this cell population has
mainly made use of the intermediate filament glial fibrillary acidic
protein (GFAP) promoter that is only expressed by a subset
of astrocytes in specific regions of the healthy brain (Takamiya
et al., 1988; Cahoy et al., 2008). Either a constitutively active or
tamoxifen-inducible GFAP promoter was used in combination
with the already mentioned DTA-system (GFAPCreERT2-DTA
mouse line, Schreiner et al., 2015) or with the bacterial
nitroreductase (NTR, GFAP-NTR mouse line). NTR is another
suicide gene where expression alone is not toxic, but the enzyme
metabolizes systemically given prodrugs into a toxic agent. The
advantage of the NTR over the suicide genes mentioned earlier
is that they are not only targeted to proliferating cells, producing
toxic agents that are independent of proliferation (Knox et al.,
1993).
Khurgel et al. (1996) used local ablation of astrocytes to reveal
their role in the healthy amygdala of adult rats. Injections of
L-AAA successfully generated a 100% astrocyte-deprived zone
with a size of 200–500 µm within 45 h after injection which
remained for further 7 days. The depletion was accompanied by
some microglial reactivity but without effects in neuronal density.
In contrast to the functional outcome after the drug-induced
astrocyte ablation (Khurgel et al., 1996), genetic ablation resulted
in severe neuronal degeneration (Cui et al., 2001). With this
specific approach, predominantly Bergmann glia, an astrocytic
subtype located in the cerebellum, were targeted in mice. The
gross ablation of Bergmann glia resulted in severe developmental
problems in the motor coordination of these mice, resembling
a hallmark of cerebellar dysfunction. The regional specificity of
the ablation observed might be explained by how the mouse
line they generated was used, as NTR-expression was detected
mainly in these cells. Recently, similar findings were obtained
in the spinal cord using the tamoxifen inducible human GFAP-
driven diphtheria toxin A (DTA)-expression (GFAPCreERT2-
DTA), where local ablation of 73% of GFAP-expressing astrocytes
was achieved in the cervical spinal cord in young adult mice
(Schreiner et al., 2015). Shortly after tamoxifen application, mice
suffered axonal degeneration accompanied by paralysis of all
limbs, while the BBB remained intact. The mechanism of action
was ascribed to the failure to buffer reactive oxygen and nitrogen
species (ROS/NOS), as the mice lack astrocytes that usually clear
the brain from these damaging substances. These results raise the
hypothesis that a GFAP-expressing subset of astrocytes is crucial
for the maintenance of neuronal health and integrity, while
other astrocytes are devoted to other functions, such as the BBB
maintenance. In contrast, another study using the non-inducible
DTA-system with an ubiquitous astrocyte specific promoter other
than GFAP, namely the aldehyde dehydrogenase 1 family member
L1 promoter (Aldh1L1), depleted ∼30% of all astrocytes in the
spinal cord and did not describe any deficits in the neuronal
support (Tsai et al., 2012). The differences between these two
studies might lie in the huge variation in ablation efficiency (73%
vs. 30%). In addition, the latter study was carried out much earlier
during development at embryonic stages. This could add to the
different outcomes, as these early appearing astrocytes might have
other functions in the CNS than during adult stages, or because
the compensation mechanisms during development are more
supportive than in the adult.
Particularly for astrocytes, the use of different ablation models
(GFAPCreERT2-DTA vs. Aldh1L1-Cre-DTA vs. GFAP- NTR vs.
TABLE 2 | Astrocyte ablation approaches under healthy and pathological conditions.
Cell type Condition Method Efficiency Physiological effect Reference
Astrocytes Health L-AAA 100% at injection site No effect on neuronal density, some
microglia reactivity
Khurgel et al., 1996
GFAP-NTR mouse line Nearly all in the
cerebellum
Neuronal degeneration of granular cells in
the cerebellum as Bergmann glia were the
major targets and motor discoordination
Cui et al., 2001
GFAPCre:iDTR mouse line and
GFAPCreERT2-DTA mouse line
73% in the spinal cord Axonal degeneration and limb paralysis due
to increase in ROS/NOS
Schreiner et al., 2015
Pathology GFAP-HSVTK mouse line Not directly specified Failure of scar formation and increased
immune invasion after EAE
Voskuhl et al., 2009
GFAP-HSVTK mouse line >95% in lesion area Increased inflammation and higher damage
after mechanical SCI
Faulkner et al., 2004
GFAP-HSVTK mouse line Not directly specified Increase in injury size and inflammation after
mechanical cortical injury
Bush et al., 1999;
Myer et al., 2006
GFAP-HSVTK mouse line Not directly specified Less immune cell activation and worsening
of myelin debris clearance after
cuprizone-induced demyelination
Skripuletz et al., 2013
GFAP-HSVTK mouse line Not directly specified No effect on neuronal survival, disease
duration and outcome in neurodegeneration
Lepore et al., 2008
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L-AAA), different areas of interest (spinal cord vs. cerebellum
vs. amygdala) and different ages (development vs. adult) are
hampering the formation of a consistent concluding statement
for these studies. Astrocytes exhibit many different morphologies
and accordingly different functions depending on the CNS region
(Robel et al., 2011). Using the GFAP-promoter as a driving-
force of astrocyte ablation is biased as GFAP is not uniformly
expressed in all astrocytes in the CNS, e.g., astrocytes located
in the cerebral white matter but not the gray matter express
GFAP (Cahoy et al., 2008; Robel et al., 2011). Therefore genes
expressed under the GFAP-promoter might only be displayed
in a subset of astrocytes with potentially specific functions that
are different from other resident astrocytes. Moreover, these
studies used different readouts in their analysis and some aspects,
like the BBB closure or neuronal damage, might simply have
been overlooked. Thus far, no study using genetic GFAP-driven
approaches has achieved ablation of cortical astrocytes under
physiological conditions in the adult brain, most likely due
to the lack of promoter-expression in these cells. To achieve
ablation of cortical astrocytes, other promoters that are (strongly)
expressed in astrocytic populations of the cerebral cortex should
be considered.
In summary, these studies demonstrated different methods to
induce the depletion of astrocytes from at least some parts of
the CNS and support the idea of astrocytes being important for
neuronal and axonal integrity on a functional basis (Figure 2;
Table 2). These ablation models could be exploited in further
experiments to address specific interaction points between
astrocytes and neurons. Most interestingly – in contrast to other
glial cell types – no studies exist that deal with the repopulation
dynamics of astrocytes after ablation or the long term effects of
this ablation, which could also be a very illuminating topic of
interest.
Astrocyte Ablation under Pathological
Conditions
Upon injury, astrocytes undergo a series of morphological and
functional changes that are commonly summarized by the
term “astrogliosis”. Astrogliosis displays a very broad spectrum
of reactivity, the hallmarks thereof being the upregulation of
structural proteins like GFAP or vimentin and the hypertrophy
of both the cell body and the processes (Wilhelmsson et al.,
2004; Sofroniew and Vinters, 2010). Additionally, some quiescent
astrocytes re-enter the cell cycle (Buffo et al., 2005), although
this occurs much later and to a lesser extent than in microglia
or NG2-glia. Reactive astrocytes are also known to elongate
around the lesion core (Wanner et al., 2013) and to release
a cascade of inflammatory signals that can strongly affect
the pathological outcome (Sofroniew, 2015). Interestingly, as
shown by repetitive in vivo imaging, astrocytes are – unlike
microglia and NG2-glia – unable to migrate into the injury
core after mechanical injury (Bardehle et al., 2013). Although
many aspects of astrocyte-specific reactions to injury are already
known, their precise role in scar formation under different
pathological conditions remains unresolved. As this question
has long been of great interest, studies that specifically ablate
FIGURE 2 | Effects and dynamics of astrocyte ablation under healthy
and pathological conditions. Under physiological conditions (left green
panel) successful astrocyte ablation has been achieved by the use of the
pharmacological drug L-α-aminoadipic acid (L-AAA) or the
GFAPCreERT2-DTA and the GFAP-NTR mouse lines. For the astrocytes, the
repopulation kinetics have not been analysed in detail yet, but these cells were
also shown to repopulate the depleted area. As a functional outcome, the
ablation did either not show an effect or had a negative effect on neuronal
survival in the cerebellum and the spinal cord. Under pathological conditions
(right orange panel) astrocyte ablation was solely achieved by the use of the
GFAP-HSVTK mouse line. However, with this model only the pool of
proliferating astrocytes can be depleted. The reduction of scar forming
astrocytes in general had a negative outcome for the injury size and severity in
spinal cord injury (SCI), mechanical brain injury and EAE. It did not affect the
pathology in a model of ALS, but this could be due to the low amount of
proliferating astrocytes in this model.
these scar forming astrocytes have already been reported almost
20 years ago.
Notably, in contrast to physiological conditions, no studies
have attempted to ablate astrocytes under pathological conditions
using pharmacological approaches, in contrast to genetic ones
that were normally used (see Table 2 bottom part). The
population targeted when utilizing the GFAP-promoter in
pathological conditions is predicted to be much higher and might
even go beyond the specific subset of cells observed in healthy
tissue. This is because a huge proportion of cortical astrocytes
upregulate GFAP upon any changes in brain homeostasis
(Takamiya et al., 1988). Using the murine GFAP-promoter to
target specific cells, many studies also use the HSVTK suicide
gene (GFAP-HSVTK mouse line; originally created by Bush
et al., 1998) as an inducer of apoptosis and to analyze the
role of astrocytic scar formation. The pathological conditions
examined with this approach spanned a broad range from
neurodegenerative diseases to traumatic brain injury.
With this ablation model, already within 1 week a myelin
oligodendrocyte glycoprotein (MOG)-induced model of EAE,
which mainly shows pathology in the spinal cord, showed robust
astrocytic death that resulted in a failure of tissue scar formation,
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increased immune cell infiltration as well as a worsened clinical
score (Voskuhl et al., 2009). Similarly, in the spinal cord, >95%
astrocyte ablation that was achieved within 7 days after small stab
wound and crush injuries led to increased tissue damage with
higher cell death and increased inflammation (Faulkner et al.,
2004). Mechanical injury to the brain identified similar findings
to studies in the spinal cord, but with greater effect. The brain
suffered more detrimental injury and greater damage, which was
induced by robust astrocyte ablation after 7 days of ganciclovir
treatment (Bush et al., 1999; Myer et al., 2006).
All these studies – independent of the pathological
conditions – presented an exacerbation of the disease outcome
after the ablation of astrocytes, with only two exceptions
presenting contradictory results. Skripuletz et al. (2013) analyzed
the outcome of the astrocyte ablation in a cuprizone-induced
demyelination model. In contrast to the other studies, less
immune cell activation – in this case specifically microglia –
could be observed, resulting in less efficient myelin clearance.
One explanation for this different outcome could be due to the
cell types involved: while all other pathological models include
the recruitment of peripheral immune cells for debris clearance,
the cuprizone model mainly relies on resident brain cells (Kipp
et al., 2009). Moreover, astrocytes might play different roles
in diverse pathological conditions. Along the same line, no
effect could be found on disease onset, duration, neuronal loss or
motor function in astrocyte ablated mice for two different models
of neurodegenerative diseases (injection of the neuroadapted
Sindbis virus (NSV) inducing neuronal death as well as in a
genetic model of ALS) (Lepore et al., 2008). However, the number
of proliferating astrocytes in these neurodegenerative disease
models is relatively low in comparison to the other models of
pathology. These contradictory results might simply be an effect
of low numbers of ablated astrocytes and more remaining ones
that are able to react, rather than of their function.
In summary, the ablation of astrocytes under pathological
conditions has given a clear functional readout for the first
time: astrocytes play a crucial role in the maintenance of
the diseased tissue and in the inhibition of secondary tissue
damage by blocking inflammation (Figure 2; Table 2). This
interpretation has to be taken with care, as only proliferating
astrocytes were ablated in all the approaches described above,
while the non-proliferating cells retained normal function that
might be different or even opposing to that of the proliferating
ones. Moreover, it is now textbook knowledge that although
scar forming astrocytes are beneficial to injury, they also
have detrimental effects on tissue regeneration (Pekny and
Pekna, 2014; Sofroniew, 2015). These aspects were only slightly
addressed in the experiments mentioned above, giving space for




Although NG2-glia are precursors of mature oligodendrocytes
within the oligodendrocyte lineage, they are often considered
an independent glial population due to their additional
characteristics. In relation to the long history of neuroscience,
NG2-glia are a relatively young cell type in terms of discovery
with identification only 30 years ago (ffrench-Constant and Raff,
1986). Although a great amount of work has been performed
on these cells, the cellular function of NG2-glia – at least in the
adult brain – remains largely a mystery. However, many cellular
characteristics have been described: NG2-glia are part of the
oligodendrocyte lineage and keep generating mature myelinating
oligodendrocytes throughout lifetime (Dimou et al., 2008; Rivers
et al., 2008; Psachoulia et al., 2009; Simon et al., 2011). Most
interestingly NG2-glia in the adult rodent brain form a tight
homeostatic network in which the cell numbers are maintained
under physiological conditions. As soon as one cell has been
lost due to either differentiation or cell death, the remaining gap
is immediately replaced by a neighboring cell (Hughes et al.,
2013). Furthermore, NG2-glia are the only highly proliferative
cells in the brain parenchyma (Dimou et al., 2008), giving
them characteristics analogous to stem cells. The most curious
aspect of NG2-glia is their ability to form functional synapses
with neurons, originally discovered in the hippocampus (Bergles
et al., 2000) but now also described in other parts of the brain
(Karadottir et al., 2005; reviewed in Sun and Dietrich, 2013). The
function of these synapses is not well understood. One interesting
aspect of these synapses is the directionality, as NG2-glia are
only able to receive neuronal signals but cannot create action
potentials on their own and propagate them further (De Biase
et al., 2010). The ablation approaches that are discussed in this
section give some insight in the role(s) of NG2-glia in the adult
brain.
Further on in the lineage, the function of mature
oligodendrocytes is clear: they are the myelin-producing
cells that insulate axons to allow a rapid saltatory conduction and
give trophic support to axons (reviewed in Nave, 2010). But as
high numbers of presumably non-myelinating oligodendrocytes
are also present in sparsely myelinated brain regions like
the gray matter of the cerebral cortex, some functional
aspects may have been overlooked. To address this question,
specific oligodendrocyte ablation approaches may deepen our
understanding of the functions of these cells.
Although NG2-glia were only discovered a short time ago
(ffrench-Constant and Raff, 1986), several approaches to deplete
these cells from the adult brain have already been developed.
As NG2-glia are well characterized on the cellular level, these
approaches mainly aimed to clarify the physiological function
of these cells. However, most of these approaches have been
rather disappointing until recently, both in terms of achieving
a NG2-glia-free brain as well as in identifying the physiological
function of these cells. The ablation of NG2-glia proved to be
more difficult in comparison with other glial cell populations:
due to their tightly regulated homeostasis (Hughes et al., 2013)
the cells escaping ablation immediately react, increasing their
proliferation rate to replace the lost cells. So far no method
has successfully ablated all NG2-glia over a long period of
time, as can be achieved successfully for microglia (compare
Table 3 and Figure 3). Although technically quite different, all of
the ablation approaches for NG2-glia commonly demonstrated
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TABLE 3 | NG2-glia ablation and differentiation block approaches under healthy conditions.
Cell type Condition Method Efficiency Physiological effect Reference





AraC infusion Almost 100% in
affected region
Fast and efficient repopulation, no
further effects analyzed
Robins et al., 2013
NG2Cre/iDTR mouse line 80% Fast repopulation, decrease in FGF2
signaling and induction of depression
like behavior




50–100% Negative effect on leptin-sensitive
neurons and energy metabolism
Djogo et al., 2016
NG2-glia oligodendrocyte
differentiation
Health Genetic depletion model ∼90% Elongation of nodes of Ranvier,
deceleration of conduction velocity
and motor dysfunctions
Schneider et al., 2016
Genetic depletion model 100% Impairment of early complex motor
skill learning
McKenzie et al., 2014;
Xiao et al., 2016
FIGURE 3 | Effects and dynamics of NG2-glia ablation under healthy
conditions. Although a relatively unknown cell type, several approaches to
deplete NG2-glia under physiological conditions, including the mitotic blocker
arabinofuranosyl cytidine (AraC), a genetic cell cycle block, X-irradiation and
the NG2Cre/iDTR mouse line. The very efficient repopulation occurred either
immediately or between 2 and 6 weeks after the ablation, depending on the
study. Although the function of NG2-glia has long been a mystery, recent
studies showed that the NG2-glia ablation negatively affects the
leptin-dependent energy metabolism and leads to a depression like behavior.
the highly efficient repopulation capacity of resident NG2-glia,
ranging from two to 6 weeks depending on the study. Two-
photon in vivo imaging demonstrated the mechanism by which
these cells become aware of their need for proliferation: they are
able to sense cell-free gaps with their fine filopodia, triggering
their migration or proliferation in order to fill the gap (Hughes
et al., 2013). Interestingly, these repopulating cells seem to be less
branched and occupy a smaller surface area (Birey and Aguirre,
2015). However, this could change over time as the cells re-grow
and re-gain their original cellular complexity.
Although the repopulation capacity of NG2-glia –
independent of the ablation approach – has fundamentally
proven to be fast, it declines with aging (Chari et al., 2003;
Birey and Aguirre, 2015). In correlation with their slowing
physiological cycling behavior, the cell cycle length increases
with aging (Psachoulia et al., 2009; Young et al., 2013). Early
studies depleting NG2-glia both in the spinal cord as well as
in the brain with high-dose X-irradiation demonstrated an
efficient repopulation within four to 6 weeks following the
ablation treatment (Chari and Blakemore, 2002; Irvine and
Blakemore, 2007). The magnitude of the cell death of NG2-glia
as well as their repopulation capacity were, however, more
efficient in developmentally younger areas like the telencephalon
(90% of ablation efficiency) compared with older ones like the
diencephalon (60% of ablation efficiency). The nature of these
regional differences might either lie in a different cell cycle length
of NG2-glia, as X-irradiation mainly affects fast cycling cells, or
it may be an issue of different developmental origins or regional
heterogeneity of those cells (Kessaris et al., 2006; Viganò et al.,
2013). The use of a single cell type-specific antibody to estimate
the efficiency of depletion can lead to an overestimation since
some proteins might be down-regulated upon a change in brain
homeostasis, as shown for neurons after injury (Pignataro et al.,
2008; Jaenisch et al., 2010). If this also holds true for NG2-glia,
the X-irradiation method would solely lead to a failure to detect
these cells with the use of an anti-NG2 antibody although they
are still present. NG2-glia are known to be the only proliferating
cells outside the neurogenic niches in the healthy adult brain
and therefore suspected to be the only cell type responding to
X-irradiation. However, after a mild irradiation injury, other cells
like microglia and astrocytes become reactive upon any cellular
death, potentially triggering their proliferation in response to
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damage. This would make them sensitive to irradiation-induced
cellular death, hence weakening the cell type specificity of this
method.
A more specific and therefore more elegant way to follow
the dynamics of ablation and repopulation of NG2-glia in vivo
by overcoming the pitfalls of detection with different antibodies,
is the use of genetically modified mouse lines to intrinsically
label NG2-glia. In a recent study, a NG2-CreER:tdTomato
mouse line permanently expressing the red fluorescent marker
“tomato” under the control of the NG2-promoter after tamoxifen
induction was used (Robins et al., 2013). As this tamoxifen-
inducible marker is permanently expressed under the ubiquitous
Rosa26-promoter, the downregulation of this locus is very
unlikely to happen. Combining this mouse line with the
intraventricular administration of AraC, a toxic agent interfering
with the cellular DNA synthesis and inducing cell death in
fast cycling but not slow or non-cycling cells (Doetsch et al.,
1999), led to rapid ablation of almost 100% of reporter-
positive NG2-glia in the hypothalamus. This ablation was then
followed by a subsequent, complete repopulation within 2 weeks.
Furthermore, with the use of BrdU-labeling experiments, insights
were provided that the repopulation of NG2-glia exclusively
occurs through proliferation of surviving adjacent NG2-glia
located in an area without AraC diffusion, but not from a NG2-
negative stem cell source.
These first ablation studies fundamentally characterized the
repopulation capacity of NG2-glia, but did not answer the
question about the NG2-glia function in the adult brain. Two
recently published NG2-glia ablation studies have so far directly
addressed the functional outcome of an at least transient
lack of NG2-glia (Birey et al., 2015; Djogo et al., 2016, see
also Figure 3). Birey et al. (2015) reported that NG2-glia
secrete the fibroblast growth factor 2 (FGF2) that directly
influences the neuronal glutamatergic transmission and the
astrocytic glutamate uptake in the prefrontal cortex. Ectopic DT
application in NG2Cre/iDTR mice expressing the DTR under an
ubiquitous promoter whose expression is driven by the NG2-
promoter, induced a selective ablation of 80% of NG2-glia in
the prefrontal cortex and resulted in a reduced FGF2 cell-to
cell signaling what induced a depression-like behavior in the
ablated mice. This work therefore indicates that NG2-glia have
a direct influence on the functionality and the properties of
the neuronal network. The mechanisms of this interaction still
remains, however, a speculation. Djogo et al. (2016) used different
methods to successfully ablate NG2-glia in the hypothalamus
(ranging from 50% in general to 100% in the treated area): (1)
AraC infusion into the 3rd ventricle, (2) genetically induced
apoptosis that is driven by the lack of a necessary cell cycle
protein Esco2 in NG2-glia, as well as (3) X-irradiation. In
this work, it could be demonstrated that under physiological
conditions NG2-glia in the hypothalamus contact dendritic
processes of leptin receptor neurons which degenerate upon
NG2-glia ablation, reducing leptin signaling. Hence, NG2-glia are
essential to maintain the function of leptin receptor neurons in
the hypothalamus, therefore proving for the first time a direct
role for NG2-glia in the maintenance of the thalamic energy
metabolism.
NG2-glia are part of the oligodendrocyte lineage and
are continuously differentiating into mature/myelinating
oligodendrocytes also throughout adulthood; hence the fate
of these two cell populations is highly connected (Dimou
et al., 2008; Simon et al., 2011; Young et al., 2013). The need
for these newly generated oligodendrocytes in the adulthood
remains, however, not well understood. A recent study tested the
hypothesis whether chronic NG2-glia ablation also influences
the oligodendrocyte differentiation and assessed potential
functional consequences (Schneider et al., 2016). This study
took advantage of the above mentioned genetic ablation model
in which the deletion of the cell cycle protein Esco2 driven
by the Sox10-promoter induces apoptosis of proliferating
NG2-glia. This approach achieved a chronic diminishment of
90% of recombined NG2-glia over a period of 16 weeks in the
white matter of the cerebral cortex while the total number of
NG2-glia remained stable. This depletion of recombined cells
yielded a reduced oligodendrogenesis that further resulted in an
elongation of the nodes of Ranvier, reduction of the saltatory
nerve conduction as well as in motor dysfunctions, therefore
demonstrating the importance of constant oligodendrogenesis
in the adult brain. Another study did not directly ablate
oligodendrocyte lineage cells, but also blocked this lineage
progression by knocking out the transcription factor Myrf under
the platelet derived growth factor receptor alpha (PDGFRα)-
promoter, resulting in the failure of NG2-glia to differentiate to
almost 100% (McKenzie et al., 2014; Xiao et al., 2016). In line
with the above mentioned study, it could be demonstrated that
the lifelong oligodendrogenesis is required for physiological
function of the brain – in this case in the very early stages of
complex motor skill learning.
While the functional outcome of a NG2-glia ablation is just at
the beginning of being understood, the role of oligodendrocytes
and their ablation in the adult brain has been subjected to studies
for several years (compare Table 4 and Figure 4), not only in the
rodent CNS (Vanderluit et al., 2000; Ghosh et al., 2011; Locatelli
et al., 2012; Oluich et al., 2012; Gritsch et al., 2014; Traka et al.,
2016) but also in other vertebrates like, e.g., in zebrafish (Chung
et al., 2013) and in xenopus (Kaya et al., 2012). Furthermore,
a broad variety of demyelination models that are used to study
Multiple Sclerosis (MS) like, e.g., cuprizone is also to a great
extent killing mature oligodendrocytes (Praet et al., 2014), but as
their primary purpose is not the study of the cell ablation, they
are not further discussed in this review.
Since oligodendrocytes do not have particular unique features
like being proliferative, all of the used approaches are taking
advantage of a toxin-induced ablation system amongst which
the DTA-system is the most common one in combination with
promoters that are specific for oligodendrocytes (summarized
in Table 4). DTA toxicity in oligodendrocytes was, e.g., directly
activated by tamoxifen-dependent Cre-induced recombination
under the proteolipid protein (Plp)-promoter (Plp-CreERT-DTA
mice), allowing a long-lasting reduction of oligodendrocytes
by 50% in the brain stem that could even be detected at
>50 weeks after recombination. This was accompanied with
the development of an autoimmune response against myelin
(Traka et al., 2016). A much faster oligodendrocyte death
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TABLE 4 | Oligodendrocyte ablation approaches under healthy conditions.
Cell type Condition Method Efficiency (%) Physiological effect Reference
Oligodendrocytes Health Plp-CreERT-DTA mouse line ∼50 Demyelination, remyelination but secondary
axonal damage with motor impairment and
seizures
Traka et al., 2016
MOGi-Cre/iDTR mouse line ∼60 Demyelination, gait disturbances, and tremor Ghosh et al., 2011
MOG-Cre;DTR mouse line ∼80 Neuropathic pain and global demyelination
independent of immune system
Gritsch et al., 2014
Mbp-DTR mouse line 26 Axonal damage without demyelination Oluich et al., 2012
Mbp-LacZ mouse line ∼50 Demyelination, remyelination, no functional
outcome analyzed
Vanderluit et al., 2000
MOGi-Cre/iDTR mouse line 60 Demyelination, motor dysfunctions, no
autoimmunity
Locatelli et al., 2012
could be achieved by the expression of the diphtheria-toxin
receptor (DTR) under the MOG-promoter, where an ectopic
DTA application for 24 days resulted in 60% oligodendrocytic
death in the corpus callosum subsequently leading to axonal
damage (Ghosh et al., 2011). Using a similar system with the
DTR-expression under the same promoter, another study could
even achieve an oligodendrocyte ablation efficiency of around
80% that was accompanied with neuropathic pain (Gritsch
et al., 2014). A similarly efficient approach with a tamoxifen
inducible MOGi-cre:iDTR mouse line could also achieve a stable
oligodendrocyte ablation of around 60% throughout the brain
(Locatelli et al., 2012). Furthermore, in another model for the
effective ablation of oligodendrocytes the DTR expression under
the myelin basic protein (MBP)-promoter was used, resulting
in an oligodendrocyte reduction of around 30% throughout the
CNS (Oluich et al., 2012). Already some time ago, Vanderluit
et al. (2000) developed a very rare, but unique system in which
oligodendrocytes express the suicide gene ß-galactosidase (LacZ)
under the MBP-promoter. Local application of fluorescein-
di-ß-galactopyranoside/3-amino-9-ethyl-carbazole (FDG/AEC)
forms a toxic precipitate after illumination that induces the death
of 50% of oligodendrocytes at the injection site in the spinal cord.
This LacZ-system approach allows the focal ablation of cells that
can even be controlled in size, while all the other described studies
used systemic drug application and hence targeted and ablated
oligodendrocytes in the complete CNS. However, this study did
not report any functional outcome of the ablation but might be a
good tool for future experiments.
Despite the differences in the ablation approach and possibly
the functional readout, all studies have in common that the
death of myelinating oligodendrocytes leads to a primary
demyelination with a persisting secondary induced axonal
damage and a subsequent spontaneous remyelination (Figure 4).
In most of the studies the demyelination and the axonal
damage are accompanied by severe motor dysfunctions like
tremor, ataxia as well as weight loss or even the development
of seizures. Although there is a severe loss of myelin and an
accumulation of myelin debris, one study reported about the
absence of the development of an autoimmune-response, what
is generally thought to happen during MS pathology (Locatelli
et al., 2012). Due to the widespread myelin loss, the biology
of these models all together creates a perfect tool for studying
remyelination besides analyzing the outcome of oligodendrocyte
death. Interestingly, Oluich et al. (2012) reported the loss of
oligodendrocytes with axonal damage but without a severe and
widespread demyelination, supporting the idea of a further
function of oligodendrocytes providing a trophic support to
axons. A possible reason for the different outcomes might be the
recombination efficiency: while the ablation rate reached between
50 and 80% in most studies, the latter one ablated less than 30%
of the oligodendrocytes that might not be enough to result in a
global demyelination but already induce some axonal damage.
In summary, the specific ablation of both NG2-glia as well
as oligodendrocytes using different approaches proved to be
similarly effective than for the other glial cell types; in case of
the NG2-glia at least transiently as they repopulate very fast (see
Table 3). While for the oligodendrocytes the functional outcome
of myelin loss and axonal damage seemed to be quite foreseeable
(Table 4), the role of NG2-glia in the adult brain remains open
and further ablation studies could give a deeper insight.
NG2-Glia/Oligodendrocyte Ablation
under Pathological Conditions
Many cellular characteristics of NG2-glia and their activation
upon different pathologies have been well described. Like
astrocytes and microglia, NG2-glia were shown to react to various
kinds of pathological insults, however, only when accompanied
with an opening of the BBB (Rhodes et al., 2006; Wang
and He, 2009; Sirko et al., 2013; Dimou and Götz, 2014).
Two-photon in vivo imaging studies even revealed a very
heterogeneous reaction of NG2-glia to injury: cell migration,
proliferation, hypertrophy, and even combined reactions are
possible (Hughes et al., 2013, von Streitberg and Dimou,
unpublished observations). Moreover, it became clear that NG2-
glia strongly increase in number and align around the lesion site
as part of the glial scar (Levine et al., 2001; Simon et al., 2011).
Besides these observations, the cellular role of NG2-glia under
pathological conditions remains unresolved – comparable to the
healthy brain.
Interestingly, unlike the other glial cell types, so far there
are no published studies that specifically ablate NG2-glia under
pathological conditions. However, as the ablation approaches
under healthy conditions are quite successful – at least
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FIGURE 4 | Effects and dynamics of oligodendrocyte ablation under
healthy conditions. Under physiological conditions successful
oligodendrocyte ablation has been achieved by the use of several
approaches: the PLP-CreERT-DTA, the MOG-Cre:DTR, the MBP-DTR, the
MBP-LacZ, and the MOGi-Cre/iDTR mouse lines. Very commonly, although
very diverse in the use of promoters and suicide genes, these approaches
induced oligodendrocyte death that in most cases resulted in primary
demyelination followed by secondary induced neuronal damage. These
observations were in most cases accompanied by a behavioral phenotype
resulting from demyelination. This phenotype could, however, take up to
50 weeks to appear, depending on the model. After a longer time,
demyelination was followed by a spontaneous remyelination. Only one study
observed axonal damage without global demyelination that could be due to
the loss of trophic axonal support.
transiently – they seem to be a very promising tool to further
tackle the functional role of these cells in pathology.
In a similar way, there are also no studies where mature
and myelinating oligodendrocytes have been specifically depleted
from the adult brain under pathological conditions. Probably
these experiments are also very unlikely to be performed in
the future, as oligodendrocytes were not shown to react to
different kinds of injury besides providing new myelin during
tissue repair, but remain rather stable. Furthermore, the death of
oligodendrocytes induces global demyelination as well as axonal
defects already under healthy conditions (Vanderluit et al., 2000;
Ghosh et al., 2011; Gritsch et al., 2014; Traka et al., 2016), which
would in the case of pathology always result in a worse outcome
and hence not be beneficial.
Summarizing this section, nothing has been published
regarding ablation studies of oligodendrocyte lineage cells under
pathological conditions. However, as especially for NG2-glia the
already established methods have proven to be effective, very
promising studies during pathological conditions will likely be
investigated in the future.
DISCUSSION AND OUTLOOK
This review summarizes the tremendous work of the last decades
on the various ablation approaches in all types of glial cells in
the adult brain (see also Tables 1–4). Although these methods
especially under healthy conditions seem quite similar at first
sight, the nature of the cells requires different methodologies.
Using the DTA or DTR-system under a cell type specific promoter
is a commonly shared and frequently used approach between
all glial cell populations. This method has the advantage that it
does not require specific features like the expression of a uniquely
expressed surface receptor that can be targeted by a drug or being
a uniquely mitotically active cell population, but can be applied
to all cell types in a similar fashion when used with a specific
promoter. The side effects of this method also seem to be rather
low and the efficiency quite high, wherefore this method is a very
good candidate to be used for future ablation studies of any cell
type.
The use of cell specific pharmacological drugs is still an
applicable and successful method to ablate cells, but has been
so far only exploited for microglia (Elmore et al., 2014; Asai
et al., 2015), and astrocytes (Takada et al., 1990; Khurgel et al.,
1996). However, although these drugs are supposed to have a very
high specificity for a cell type or a surface receptor, there might
still be some receptor expression in other cell types, resulting in
controversial outcomes of different studies like for instance in
the case of the L-AAA-induced astrocyte ablation (Saffran and
Crutcher, 1987; Khurgel et al., 1996). The same becomes true for
microglia: although there are no controversial reports about the
application of PLX3397 to induce myeloid cell death, it is already
known that the drug might cross-react with some other receptor-
kinases like, e.g., the platelet-derived growth factor receptor
(PDGFR) making also other cells expressing those susceptible to
cell death (Cornelis et al., 2005; Chitu et al., 2012; Thompson
et al., 2015). For NG2-glia there are until now no cell specific
drugs available, probably due to the lack of a unique promising
target receptor on those cells. In general, the use of cell specific
pharmacological drugs still represents an easy and effective way
for cell specific ablation studies that does in addition not require
the use of expensive transgenic mouse lines. However, the risk of
also targeting other cell populations and hence inducing potential
secondary effects is still high and the experiments should – as
always – be interpreted with caution.
Another very commonly used but also very cell specific
approach is the application of X-irradiation to a specific region
of interest. But this method can mainly be used for the ablation
of NG2-glia, as they carry the unique feature of being the only
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proliferative cells outside the neurogenic niches, while microglia
and astrocytes generally survive this treatment as they do not
cycle under physiological conditions (Xu et al., 2007; Buffo
et al., 2008). This is in accordance with findings of human
X-irradiation studies, where at least low doses of irradiation,
do not directly affect the brain but induce “late delayed” effects
that do not become evident directly after the treatment but
only at later time points, predominantly in the corpus callosum
(reviewed in Loganovsky, 2009; Citrin et al., 2010). In this
region, the proportion of slowly cycling NG2-glia was shown
to be high in humans (Geha et al., 2010) and this region is
therefore predominantly affected. However, it has also proven
that X-irradiation is not very efficient to ablate NG2-glia, as
this method mainly targets actively cycling cells, but NG2-
glia were shown to be a very slowly cycling cell population
and to have a very long cell cycle due to an extended G1-
resting phase (Simon et al., 2011). This unique property is
also the reason why infusion of the mitotic blocker AraC
specifically ablates NG2-glia (Robins et al., 2013; Djogo et al.,
2016).
Most interestingly, although using somehow similar
approaches, the ablation efficiencies within the same cell
population was highly variable between the different studies
(compare Tables 1–4), especially for oligodendrocytes, where
the ablation efficiency spanned from 26 to 80%. This variation
could most likely first be explained by the use of different
promoters (like MBP or MOG) that are driving the suicide gene
expression. Even when using the same promoter, variations in
the recombination rate and hence the ablation efficiency can
occur, as the cloning strategy of the transgenic animals and
the induction protocols can highly influence the recombination
rate. The application of the systemic prodrug that can either
be given by injections or in the chow would increase the
variability between the different studies, as one application form
might be more efficient than another. All these arguments do
also apply when comparing the area specificity of the ablation
approaches that also showed a high variability especially for
astrocytes.
After injury, the ablation approaches between at least
microglia and astrocytes (as so far no studies have been
performed for cells of the oligodendrocyte lineage), are mainly
using the TK as a mediator for apoptosis. Again, these studies
proved to be quite efficient, both in terms of ablation efficiency
and functional readout; might however be accompanied by
some disadvantages. TK-mediated cell ablation mainly targets
proliferating cells, but not those that are quiescent (Bush
et al., 1999), therefore this method does not really display an
ablation of the complete cell population but more a paralysis
of the injury-driven increase that was observed by in vivo
imaging studies (Davalos et al., 2005). Especially for astrocytes,
this induces a bias for a specific proliferating subset of cells,
as only ∼20% of all astrocytes seem to be able to re-enter
the cell cycle after injury (Bardehle et al., 2013). Hence, the
analysis of the function of another subpopulation of quiescent
astrocytes would require another ablation method. For microglia
this bias does not seem to be so pronounced, as a higher
proportion of microglia is able to proliferate after a pathological
insult (Amat et al., 1996), and therefore the function of the
whole population seems to be addressed. Thinking forward,
this method could be an appropriate approach to ablate also
NG2-glia after injury, as 80% of NG2-glia have been shown
to proliferate after cortical stab wound injury (Simon et al.,
2011).
Brain research generally has the tendency to look at different
cell types in a very isolated way, as many of these ablation
studies also did, both in the healthy and the pathological brain.
In those studies that also determined the consequences of the
ablation in other cell types, only the cell numbers were quantified
but not their function. However, it is nowadays well accepted
that a panglial network exists that is highly connected with
each other via connexins (May et al., 2013) and especially after
injury seems to also communicate with each other. It is, e.g.,
known that macrophages after injury are able to influence NG2-
glia by secretory mechanisms (Rhodes et al., 2006), or that
astrocytes are important for the initiation of the macrophage
reactivity (Farina et al., 2007). The ablation of one cell type
in the brain could also elicit a reaction in other cell types
even when only on the signaling level. Unpublished data from
our lab also indicate a cellular communication between the
different glial cell types under pathological conditions: when
genetically ablating NG2-glia after cortical stab wound injury,
the cellular reactions of both astrocytes and microglia was
hampered (Schneider and Dimou, unpublished observations),
similar to what has already been observed in the spinal
cord after a diminished NG2-glia reactivity (Rodriguez et al.,
2014).
Taking these new findings into account, the overall sum of
glial ablation studies can already provide insights in the cellular
characteristics of these cells and help to better understand their
function in both the healthy as well as the pathological brain.
However, looking to the future, they could be further exploited to
investigate the almost unknown terrain of glial cell interactions
in vivo.
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